Aikawa Y - Search Results

1

A selective inhibition of c-Fos/activator protein-1 as a potential therapeutic target for intervertebral disc degeneration and associated pain.

Makino H, Seki S, Yahara Y, Shiozawa S, Aikawa Y, Motomura H, Nogami M, Watanabe K, Sainoh T, Ito H, Tsumaki N, Kawaguchi Y, Yamazaki M, Kimura T. Makino H, et al. Among authors: aikawa y. Sci Rep. 2017 Dec 5;7(1):16983. doi: 10.1038/s41598-017-17289-y. Sci Rep. 2017. PMID: 29208967 Free PMC article.

2

A selective c-Fos/AP-1 inhibitor prevents cartilage destruction and subsequent osteophyte formation.

Motomura H, Seki S, Shiozawa S, Aikawa Y, Nogami M, Kimura T. Motomura H, et al. Among authors: aikawa y. Biochem Biophys Res Commun. 2018 Mar 4;497(2):756-761. doi: 10.1016/j.bbrc.2018.02.147. Epub 2018 Feb 21. Biochem Biophys Res Commun. 2018. PMID: 29476740

3

Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1.

Aikawa Y, Morimoto K, Yamamoto T, Chaki H, Hashiramoto A, Narita H, Hirono S, Shiozawa S. Aikawa Y, et al. Nat Biotechnol. 2008 Jul;26(7):817-23. doi: 10.1038/nbt1412. Epub 2008 Jun 29. Nat Biotechnol. 2008. PMID: 18587386

4

Discovery of nonpeptidic small-molecule AP-1 inhibitors: lead hopping based on a three-dimensional pharmacophore model.

Tsuchida K, Chaki H, Takakura T, Kotsubo H, Tanaka T, Aikawa Y, Shiozawa S, Hirono S. Tsuchida K, et al. Among authors: aikawa y. J Med Chem. 2006 Jan 12;49(1):80-91. doi: 10.1021/jm050550d. J Med Chem. 2006. PMID: 16392794

5

Design, synthesis, and biological evaluation of new cyclic disulfide decapeptides that inhibit the binding of AP-1 to DNA.

Tsuchida K, Chaki H, Takakura T, Yokotani J, Aikawa Y, Shiozawa S, Gouda H, Hirono S. Tsuchida K, et al. Among authors: aikawa y. J Med Chem. 2004 Aug 12;47(17):4239-46. doi: 10.1021/jm049890+. J Med Chem. 2004. PMID: 15293995

6

[General pharmacology of T-3761, a new oral quinolone antibacterial agent (1). Effect on the central nervous system].

Furuhata K, Hiraiwa T, Ono S, Tanaka K, Shimotori T, Makino S, Kitamura K, Aikawa Y, Izumi Y, Kimura T, et al. Furuhata K, et al. Among authors: aikawa y. Jpn J Antibiot. 1995 May;48(5):692-705. Jpn J Antibiot. 1995. PMID: 7637204 Japanese.

7

T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts.

Tanaka K, Kawasaki H, Kurata K, Aikawa Y, Tsukamoto Y, Inaba T. Tanaka K, et al. Among authors: aikawa y. Jpn J Pharmacol. 1995 Apr;67(4):305-14. doi: 10.1254/jjp.67.305. Jpn J Pharmacol. 1995. PMID: 7650864 Free article.

8

Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells.

Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, Inoue K, Kusaka Y, Kondo M, Sano H. Kohno M, et al. Among authors: aikawa y. J Rheumatol. 2001 Dec;28(12):2591-6. J Rheumatol. 2001. PMID: 11764202

9

An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation.

Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. Aikawa Y, et al. Inflamm Res. 2002 Apr;51(4):188-94. doi: 10.1007/pl00000291. Inflamm Res. 2002. PMID: 12058956

10

Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4'-1-benzopyran-4-o ne. 2nd communication: effect on the arachidonic acid cascades.

Tanaka K, Makino S, Shimotori T, Aikawa Y, Inaba T, Yoshida C. Tanaka K, et al. Among authors: aikawa y. Arzneimittelforschung. 1992 Jul;42(7):945-50. Arzneimittelforschung. 1992. PMID: 1329779

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

198 results

Search Page

Filters